Sudden-onset Hypoglycemia Following Fluid Replacement in a Patient with Dapagliflozin-induced Diabetic Ketoacidosis Without Prior Insulin Use: Case Report
Name:
1567006974-20190828-218-1snxidr.pdf
Size:
1.783Mb
Format:
PDF
Description:
Final Published Version
Affiliation
Univ Arizona, Coll Med Phoenix, Endocrinol Diabet & MetabIssue Date
2019-08-21Keywords
diabetic ketoacidosishypoglycemia
metformin
sodium-glucose co transporter-2 (sglt2) inhibitors
Metadata
Show full item recordPublisher
CUREUS INCCitation
Elshimy G, Correa R (August 21, 2019) Sudden-onset Hypoglycemia Following Fluid Replacement in a Patient with Dapagliflozin-induced Diabetic Ketoacidosis Without Prior Insulin Use: Case Report. Cureus 11(8): e5448. doi:10.7759/cureus.5448Journal
CUREUSRights
© Copyright 2019 Elshimy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Euglycemic diabetic ketoacidosis (DKA) is a known complication of sodium-glucose co-transporter 2 (SGLT-2) inhibitors that have been reported in the literature. The prevalence of this side effect is growing and the exact mechanism of action on why this happens is unknown. Hypoglycemia events are very rare in diabetic patients using SGLT-2 inhibitors and/or metformin when they have normal kidney function. We report a novel complication of hypoglycemia that occurred during the course of treatment of SGLT2 inhibitor-induced DKA in a patient with type 2 diabetes mellitus (T2DM) on the dapagliflozin-metformin combination.Note
Open access journalISSN
2168-8184PubMed ID
31489272Version
Final published versionae974a485f413a2113503eed53cd6c53
10.7759/cureus.5448
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © Copyright 2019 Elshimy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0.
Related articles
- SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
- Authors: He Z, Lam K, Zhao W, Yang S, Li Y, Mo J, Gao S, Liang D, Qiu K, Huang M, Wu J
- Issue date: 2023 Mar
- Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis.
- Authors: Iqbal I, Hamid M, Khan MAA, Kainat A, Tariq S
- Issue date: 2019 Nov 7
- Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
- Authors: Diaz-Ramos A, Eilbert W, Marquez D
- Issue date: 2019 Sep 5
- [Euglycemic Diabetic Ketoacidosis Caused by a Sodium-glucose Co-transporter (SGLT) 2 Inhibitor after Coronary Artery Bypass Grafting].
- Authors: Kameda Y, Kato M, Inoue B, Yamazaki S, Sahara N, Aoki T, Nagashima Y, Nemoto N, Anzai H, Araki W, Kobayashi N
- Issue date: 2019 May
- A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.
- Authors: Patel K, Nair A
- Issue date: 2022 Sep